Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased LiquidityGlobeNewsWire • 08/04/25
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation ProductsGlobeNewsWire • 07/30/25
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025GlobeNewsWire • 07/29/25
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025GlobeNewsWire • 04/28/25
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 MillionBenzinga • 03/11/25
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025GlobeNewsWire • 02/28/25
BVS Stock Gains Post Divestiture of Advanced Rehabilitation BusinessZacks Investment Research • 01/03/25
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed PartnersGlobeNewsWire • 01/02/25
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a BetZacks Investment Research • 12/06/24
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024GlobeNewsWire • 10/29/24